Selenium and chronic diseases: A nutritional genomics perspective

Nutrients

Volumn 7, Issue 5, 2015, Pages 3621-3651

  Méplan, Catherine ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cancer; Glutathione peroxidase; Nutritional genomics; Selenium; Selenoprotein P; Single nucleotide polymorphisms

Indexed keywords

GLUTATHIONE PEROXIDASE; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; SELENIUM; SELENOPROTEIN; THIOREDOXIN REDUCTASE 1; THIOREDOXIN REDUCTASE 2; SELENIUM DERIVATIVE;

BLADDER CANCER; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; COLORECTAL CANCER; CROHN DISEASE; DNA DAMAGE; ENVIRONMENTAL STRESS; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMEOSTASIS; HUMAN; INFLAMMATORY BOWEL DISEASE; KASHIN BECK DISEASE; LARYNX CANCER; LUNG CANCER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; NUTRIGENOMICS; NUTRITIONAL STATUS;

CHRONIC DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NUTRIGENOMICS; NUTRITIONAL STATUS; POLYMORPHISM, SINGLE NUCLEOTIDE; SELENIUM; SELENIUM COMPOUNDS; SELENOPROTEINS;

EID: 84929378554     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7053621     Document Type: Review

References (116)

1. Thomson, C. D. Selenium and iodine intakes and status in New Zealand and Australia. Br. J. Nutr. 2004, 91, 661-672.
2. Rayman, M. P. The argument for increasing selenium intake. Proc. Nutr. Soc. 2002, 61, 203-215.
3. Koivistoinen, P.; Huttunen, J. K. Selenium in food and nutrition in finland. An overview on research and action. Ann. Clin. Res. 1986, 18, 13-17.
4. Xia, Y.; Hill, K. E.; Byrne, D. W.; Xu, J.; Burk, R. F. Effectiveness of selenium supplements in a low-selenium area of china. Am. J. Clin. Nutr. 2005, 81, 829-834.
5. Shamberger, R. J.; Frost, D. V. Possible protective effect of selenium against human cancer. Can. Med. Assoc. J. 1969, 100, 682.
6. Waegeneers, N.; Thiry, C.; De Temmerman, L.; Ruttens, A. Predicted dietary intake of selenium by the general adult population in belgium. Food Addit. Contam. Part A 2013, 30, 278-285.
7. Bellinger, F. P.; Raman, A. V.; Reeves, M. A.; Berry, M. J. Regulation and function of selenoproteins in human disease. Biochem. J. 2009, 422, 11-22.
8. Berry, M. J.; Tujebajeva, R. M.; Copeland, P. R.; Xu, X. M.; Carlson, B. A.; Martin, G. W., 3rd; Low, S. C.; Mansell, J. B.; Grundner-Culemann, E.; Harney, J. W.; et al. Selenocysteine incorporation directed from the 3'UTR: Characterization of eukaryotic efsec and mechanistic implications. Biofactors 2001, 14, 17-24.
9. Bermano, G.; Nicol, F.; Dyer, J. A.; Sunde, R. A.; Beckett, G. J.; Arthur, J. R.; Hesketh, J. E. Tissue-specific regulation of selenoenzyme gene expression during selenium deficiency in rats. Biochem. J. 1995, 311, 425-430.
10. Schomburg, L.; Schweizer, U. Hierarchical regulation of selenoprotein expression and sex-specific effects of selenium. Biochim. Biophys. Acta. 2009, 1790, 1453-1462.
11. Meplan, C.; Nicol, F.; Burtle, B. T.; Crosley, L. K.; Arthur, J. R.; Mathers, J. C.; Hesketh, J. E. Relative abundance of selenoprotein p isoforms in human plasma depends on genotype, se intake, and cancer status. Antioxid. Redox. Signal. 2009, 11, 2631-2640.
12. Meplan, C.; Crosley, L. K.; Nicol, F.; Beckett, G. J.; Howie, A. F.; Hill, K. E.; Horgan, G.; Mathers, J. C.; Arthur, J. R.; Hesketh, J. E. Genetic polymorphisms in the human selenoprotein p gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the Selgen study). Faseb. J. 2007, 21, 3063-3074.
13. Gentschew, L.; Bishop, K. S.; Han, D. Y.; Morgan, A. R.; Fraser, A. G.; Lam, W. J.; Karunasinghe, N.; Campbell, B.; Ferguson, L. R. Selenium, selenoprotein genes and crohn's disease in a case-control population from Auckland, New Zealand. Nutrients 2012, 4, 1247-1259.
14. Hu, Y. J.; Korotkov, K. V.; Mehta, R.; Hatfield, D. L.; Rotimi, C. N.; Luke, A.; Prewitt, T. E.; Cooper, R. S.; Stock, W.; Vokes, E. E.; et al. Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human sep15 gene. Cancer. Res. 2001, 61, 2307-2310.
15. Korotkov, K. V.; Kumaraswamy, E.; Zhou, Y.; Hatfield, D. L.; Gladyshev, V. N. Association between the 15-kda selenoprotein and UDP-glucose: Glycoprotein glucosyltransferase in the endoplasmic reticulum of mammalian cells. J. Biol. Chem. 2001, 276, 15330-15336.
16. Meplan, C.; Crosley, L. K.; Nicol, F.; Horgan, G. W.; Mathers, J. C.; Arthur, J. R.; Hesketh, J. E. Functional effects of a common single-nucleotide polymorphism (GPx4c718t) in the glutathione peroxidase 4 gene: Interaction with sex. Am. J. Clin. Nutr. 2008, 87, 1019-1027.
17. Bermano, G.; Arthur, J. R.; Hesketh, J. E. Role of the 3′ untranslated region in the regulation of cytosolic glutathione peroxidase and phospholipid-hydroperoxide glutathione peroxidase gene expression by selenium supply. Biochem. J. 1996, 320, 891-895.
18. Gautrey, H.; Nicol, F.; Sneddon, A. A.; Hall, J.; Hesketh, J. A T/C polymorphism in the GPx4 3′UTR affects the selenoprotein expression pattern and cell viability in transfected caco-2 cells. Biochim. Biophys. Acta. 2011, 1810, 284-291.
19. Hu, Y. J.; Diamond, A. M. Role of glutathione peroxidase 1 in breast cancer: Loss of heterozygosity and allelic differences in the response to selenium. Cancer Res. 2003, 63, 3347-3351.
20. Ravn-Haren, G.; Olsen, A.; Tjonneland, A.; Dragsted, L. O.; Nexo, B. A.; Wallin, H.; Overvad, K.; Raaschou-Nielsen, O.; Vogel, U. Associations between GPx1 pro198leu polymorphism, erythrocyte GPx activity, alcohol consumption and breast cancer risk in a prospective cohort study. Carcinogenesis 2006, 27, 820-825.
21. Franke, A.; McGovern, D. P. B.; Barrett, J. C.; Wang, K.; Radford-Smith, G. L.; Ahmad, T.; Lees, C. W.; Balschun, T.; Lee, J.; Roberts, R.; et al. Genome-wide meta-analysis increases to 71 the number of confirmed crohn's disease susceptibility loci. Nat. Genet. 2010, 42, 1118-1125.
22. Jostins, L.; Ripke, S.; Weersma, R. K.; Duerr, R. H.; McGovern, D. P.; Hui, K. Y.; Lee, J. C.; Schumm, L. P.; Sharma, Y.; Anderson, C. A.; et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491, 119-124.
23. Vithana, E. N.; Khor, C. C.; Qiao, C. Y.; Nongpiur, M. E.; George, R.; Chen, L. J.; Do, T.; Abu-Amero, K. K.; Huang, C. K.; Low, S.; et al. Genome-wide association analyses identify three new susceptibility loci for primary angle closure glaucoma. Nat. Genet. 2012, 44, 1142-1146.
24. Ye, Z.; Vasco, D. A.; Carter, T. C.; Brilliant, M. H.; Schrodi, S. J.; Shukla, S. K. Genome wide association study of SNP-, gene-, and pathway-based approaches to identify genes influencing susceptibility to staphylococcus Aureus infections. Front. Genet. 2014, 5, 125.
25. Wang, M.; Kaufman, R. J. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat. Rev. Cancer 2014, 14, 581-597.
26. Westlake, S. Cancer incidence and mortality in the United Kingdom and constituent countries, 2004-06. Health Stat. Q. 2009, 43, 56-62.
27. Kamangar, F.; Dores, G. M.; Anderson, W. F. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006, 24, 2137-2150.
28. Polyak, K. Breast cancer: Origins and evolution. J. Clin. Invest. 2007, 117, 3155-3163.
29. Ambrosone, C. B. Oxidants and antioxidants in breast cancer. Antioxid. Redox. Signal. 2000, 2, 903-917.
30. Babaknejad, N.; Sayehmiri, F.; Sayehmiri, K.; Rahimifar, P.; Bahrami, S.; Delpesheh, A.; Hemati, F.; Alizadeh, S. The relationship between selenium levels and breast cancer: A systematic review and meta-analysis. Biol. Trace. Elem. Res. 2014, 159, 1-7.
31. Kulak, M. V.; Cyr, A. R.; Woodfield, G. W.; Bogachek, M.; Spanheimer, P. M.; Li, T.; Price, D. H.; Domann, F. E.; Weigel, R. J. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer. Oncogene 2013, 32, 4043-4051.
32. Jardim, B. V.; Moschetta, M. G.; Leonel, C.; Gelaleti, G. B.; Regiani, V. R.; Ferreira, L. C.; Lopes, J. R.; Zuccari, D. A. Glutathione and glutathione peroxidase expression in breast cancer: An immunohistochemical and molecular study. Oncol. Rep. 2013, 30, 1119-1128.
33. Bera, S.; Weinberg, F.; Ekoue, D. N.; Ansenberger-Fricano, K.; Mao, M.; Bonini, M. G.; Diamond, A. M. Natural allelic variations in glutathione peroxidase-1 affect its subcellular localization and function. Cancer Res. 2014, 74, 5118-5126.
34. Knight, J. A.; Onay, U. V.; Wells, S.; Li, H.; Shi, E. J.; Andrulis, I. L.; Ozcelik, H. Genetic variants of gpx1 and sod2 and breast cancer risk at the ontario site of the breast cancer family registry. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 146-149.
35. Meplan, C.; Dragsted, L. O.; Ravn-Haren, G.; Tjonneland, A.; Vogel, U.; Hesketh, J. Association between polymorphisms in glutathione peroxidase and selenoprotein p genes, glutathione peroxidase activity, HRT use and breast cancer risk. PLoS One 2013, 8, e73316.
36. Ha, E. J.; Smith, A. M. Plasma selenium and plasma and erythrocyte glutathione peroxidase activity increase with estrogen during the menstrual cycle. J. Am. Coll. Nutr. 2003, 22, 43-51.
37. Nam, S. Y.; Baek, I. J.; Lee, B. J.; In, C. H.; Jung, E. Y.; Yon, J. M.; Ahn, B.; Kang, J. K.; Yu, W. J.; Yun, Y. W. Effects of 17beta-estradiol and tamoxifen on the selenoprotein phospholipid hydroperoxide glutathione peroxidase (PHGPx) mrna expression in male reproductive organs of rats. J. Reprod. Dev. 2003, 49, 389-396.
38. Yager, J. D. Endogenous estrogens as carcinogens through metabolic activation. J. Natl. Cancer Inst. Monogr. 2000, 27, 67-73.
39. Nasr, M. A.; Hu, Y. J.; Diamond, A. M. Allelic loss at the sep15 locus in breast cancer. Cancer Therapy. 2003, 1, 293-298.
40. Udler, M.; Maia, A. T.; Cebrian, A.; Brown, C.; Greenberg, D.; Shah, M.; Caldas, C.; Dunning, A.; Easton, D.; Ponder, B.; et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J. Clin. Oncol. 2007, 25, 3015-3023.
41. Pellatt, A. J.; Wolff, R. K.; John, E. M.; Torres-Mejia, G.; Hines, L. M.; Baumgartner, K. B.; Giuliano, A. R.; Lundgreen, A.; Slattery, M. L. Sepp1 influences breast cancer risk among women with greater native american ancestry: The breast cancer health disparities study. PLoS One 2013, 8, e80554.
42. Ahn, J.; Gammon, M. D.; Santella, R. M.; Gaudet, M. M.; Britton, J. A.; Teitelbaum, S. L.; Terry, M. B.; Neugut, A. I.; Ambrosone, C. B. No association between glutathione peroxidase Pro198Leu polymorphism and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 2459-2461.
43. Cox, D. G.; Hankinson, S. E.; Kraft, P.; Hunter, D. J. No association between GPX1 Pro198Leu and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 1821-1822.
44. Cebrian, A.; Pharoah, P. D.; Ahmed, S.; Smith, P. L.; Luccarini, C.; Luben, R.; Redman, K.; Munday, H.; Easton, D. F.; Dunning, A. M.; et al. Tagging single-nucleotide polymorphisms in antioxidant defense enzymes and susceptibility to breast cancer. Cancer Res. 2006, 66, 1225-1233.
45. Ferlay, J.; Shin, H. R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D. M. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int. J. Cancer 2010, 127, 2893-2917.
46. Center, M. M.; Jemal, A.; Lortet-Tieulent, J.; Ward, E.; Ferlay, J.; Brawley, O.; Bray, F. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 2012, 61, 1079-1092.
47. Clark, L. C.; Combs, G. F., Jr.; Turnbull, B. W.; Slate, E. H.; Chalker, D. K.; Chow, J.; Davis, L. S.; Glover, R. A.; Graham, G. F.; Gross, E. G.; et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. JAMA 1996, 276, 1957-1963.
48. Duffield-Lillico, A. J.; Slate, E. H.; Reid, M. E.; Turnbull, B. W.; Wilkins, P. A.; Combs, G. F., Jr.; Park, H. K.; Gross, E. G.; Graham, G. F.; Stratton, M. S.; et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J. Natl. Cancer Inst. 2003, 95, 1477-1481.
49. Klein, E. A.; Thompson, I. M.; Lippman, S. M.; Goodman, P. J.; Albanes, D.; Taylor, P. R.; Coltman, C. Select: The selenium and vitamin E cancer prevention trial: Rationale and design. Prostate. Cancer Prostatic. Dis. 2000, 3, 145-151.
50. Lippman, S. M.; Klein, E. A.; Goodman, P. J.; Lucia, M. S.; Thompson, I. M.; Ford, L. G.; Parnes, H. L.; Minasian, L. M.; Gaziano, J. M.; Hartline, J. A.; et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin e cancer prevention trial (select). JAMA 2009, 301, 39-51.
51. Kristal, A. R.; Darke, A. K.; Morris, J. S.; Tangen, C. M.; Goodman, P. J.; Thompson, I. M.; Meyskens, F. L., Jr.; Goodman, G. E.; Minasian, L. M.; Parnes, H. L.; et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J. Natl. Cancer Inst. 2014, 106, djt456.
52. Geybels, M. S.; van den Brandt, P. A.; Schouten, L. J.; van Schooten, F. J.; van Breda, S. G.; Rayman, M. P.; Green, F. R.; Verhage, B. A. Selenoprotein gene variants, toenail selenium levels, and risk for advanced prostate cancer. J. Natl. Cancer Inst. 2014, 106, dju003.
53. Van den Brandt, P. A.; Zeegers, M. P.; Bode, P.; Goldbohm, R. A. Toenail selenium levels and the subsequent risk of prostate cancer: A prospective cohort study. Cancer Epidemiol. Biomarkers Prev. 2003, 12, 866-871.
54. West, D. W.; Slattery, M. L.; Robison, L. M.; French, T. K.; Mahoney, A. W. Adult dietary intake and prostate cancer risk in Utah: A case-control study with special emphasis on aggressive tumors. Cancer Causes Control 1991, 2, 85-94.
55. Etminan, M.; FitzGerald, J. M.; Gleave, M.; Chambers, K. Intake of selenium in the prevention of prostate cancer: A systematic review and meta-analysis. Cancer Causes Control 2005, 16, 1125-1131.
56. Dennert, G.; Zwahlen, M.; Brinkman, M.; Vinceti, M.; Zeegers, M. P.; Horneber, M. Selenium for preventing cancer. Cochrane Database Syst. Rev. 2011, 11, doi: 10. 1002/14651858. CD005195. pub2. Available online: http://www. ncbi. nlm. nih. gov/pubmed/21563143 (accessed on 11 May 2015).
57. Vinceti, M.; Dennert, G.; Crespi, C. M.; Zwahlen, M.; Brinkman, M.; Zeegers, M. P.; Horneber, M.; D'Amico, R.; Del Giovane, C. Selenium for preventing cancer. Cochrane Database Syst. Rev. 2014, 3, doi: 10. 1002/14651858. CD005195. pub3. Available online: http://www. ncbi. nlm. nih. gov/pubmed/24683040 (accessed on 11 May 2015).
58. Hurst, R.; Hooper, L.; Norat, T.; Lau, R.; Aune, D.; Greenwood, D. C.; Vieira, R.; Collings, R.; Harvey, L. J.; Sterne, J. A.; et al. Selenium and prostate cancer: Systematic review and meta-analysis. Am. J. Clin. Nutr. 2012, 96, 111-122.
59. Meplan, C.; Hesketh, J. Selenium and cancer: A story that should not be forgotten-insights from genomics. Cancer Treat. Res. 2014, 159, 145-166.
60. Steinbrecher, A.; Meplan, C.; Hesketh, J.; Schomburg, L.; Endermann, T.; Jansen, E.; Akesson, B.; Rohrmann, S.; Linseisen, J. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol. Biomarkers Prev. 2010, 19, 2958-2968.
61. Cooper, M. L.; Adami, H. O.; Gronberg, H.; Wiklund, F.; Green, F. R.; Rayman, M. P. Interaction between single nucleotide polymorphisms in selenoprotein p and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res. 2008, 68, 10171-10177.
62. Abe, M.; Xie, W.; Regan, M. M.; King, I. B.; Stampfer, M. J.; Kantoff, P. W.; Oh, W. K.; Chan, J. M. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int. 2011, 107, 126-134.
63. Choi, J. Y.; Neuhouser, M. L.; Barnett, M.; Hudson, M.; Kristal, A. R.; Thornquist, M.; King, I. B.; Goodman, G. E.; Ambrosone, C. B. Polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smokers. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1115-1120.
64. Arsova-Sarafinovska, Z.; Matevska, N.; Eken, A.; Petrovski, D.; Banev, S.; Dzikova, S.; Georgiev, V.; Sikole, A.; Erdem, O.; Sayal, A.; et al. Glutathione peroxidase 1 (GPx1) genetic polymorphism, erythrocyte GPX activity, and prostate cancer risk. Int. Urol. Nephrol. 2009, 41, 63-70.
65. Karunasinghe, N.; Han, D. Y.; Goudie, M.; Zhu, S. T.; Bishop, K.; Wang, A.; Duan, H.; Lange, K.; Ko, S.; Medhora, R.; et al. Prostate disease risk factors among a New Zealand cohort. J. Nutrigenet. Nutrige. 2012, 5, 339-351.
66. Penney, K. L.; Li, H.; Mucci, L. A.; Loda, M.; Sesso, H. D.; Stampfer, M. J.; Ma, J. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate 2013, 73, 700-705.
67. Penney, K. L.; Schumacher, F. R.; Li, H.; Kraft, P.; Morris, J. S.; Kurth, T.; Mucci, L. A.; Hunter, D. J.; Kantoff, P. W.; Stampfer, M. J.; et al. A large prospective study of sep15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev. Res. 2010, 3, 604-610.
68. Meplan, C.; Rohrmann, S.; Steinbrecher, A.; Schomburg, L.; Jansen, E.; Linseisen, J.; Hesketh, J. Polymorphisms in thioredoxin reductase and selenoprotein K genes and selenium status modulate risk of prostate cancer. PLoS One 2012, 7, e48709.
69. Geybels, M. S.; Hutter, C. M.; Kwon, E. M.; Ostrander, E. A.; Fu, R.; Feng, Z.; Stanford, J. L.; Peters, U. Variation in selenoenzyme genes and prostate cancer risk and survival. Prostate 2013, 73, 734-742.
70. Gerstenberger, J. P.; Bauer, S. R.; Van Blarigan, E. L.; Sosa, E.; Song, X.; Witte, J. S.; Carroll, P. R.; Chan, J. M. Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence. Prostate 2015, 75, 60-69.
71. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan 2012. Int. J. Cancer 2015, 136, E359-E386.
72. Cappellani, A.; Zanghi, A.; Di Vita, M.; Cavallaro, A.; Piccolo, G.; Veroux, P.; Lo Menzo, E.; Cavallaro, V.; de Paoli, P.; Veroux, M.; et al. Strong correlation between diet and development of colorectal cancer. Fron. Biosci. 2013, 18, 190-198.
73. Peters, U.; Takata, Y. Selenium and the prevention of prostate and colorectal cancer. Mol. Nutr. Food Res. 2008, 52, 1261-1272.
74. Duffield-Lillico, A. J.; Reid, M. E.; Turnbull, B. W.; Combs, G. F., Jr.; Slate, E. H.; Fischbach, L. A.; Marshall, J. R.; Clark, L. C. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: A summary report of the nutritional prevention of cancer trial. Cancer Epidemiol. Biomarkers Prev. 2002, 11, 630-639.
75. Hughes, D. J.; Fedirko, V.; Jenab, M.; Schomburg, L.; Meplan, C.; Freisling, H.; Bueno-de-Mesquita, H. B.; Hybsier, S.; Becker, N. P.; Czuban, M.; et al. Selenium status is associated with colorectal cancer risk in the european prospective investigation of cancer and nutrition cohort. Int. J. Cancer 2015, 136, 1149-1161.
76. Peters, U.; Chatterjee, N.; Hayes, R. B.; Schoen, R. E.; Wang, Y.; Chanock, S. J.; Foster, C. B. Variation in the selenoenzyme genes and risk of advanced distal colorectal adenoma. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 1144-1154.
77. Bermano, G.; Pagmantidis, V.; Holloway, N.; Kadri, S.; Mowat, N. A.; Shiel, R. S.; Arthur, J. R.; Mathers, J. C.; Daly, A. K.; Broom, J.; et al. Evidence that a polymorphism within the 3′UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer. Genes Nutr. 2007, 2, 225-232.
78. Meplan, C.; Hughes, D. J.; Pardini, B.; Naccarati, A.; Soucek, P.; Vodickova, L.; Hlavata, I.; Vrana, D.; Vodicka, P.; Hesketh, J. E. Genetic variants in selenoprotein genes increase risk of colorectal cancer. Carcinogenesis 2010, 31, 1074-1079.
79. Sutherland, A.; Kim, D. H.; Relton, C.; Ahn, Y. O.; Hesketh, J. Polymorphisms in the selenoprotein s and 15-kda selenoprotein genes are associated with altered susceptibility to colorectal cancer. Genes Nutr. 2010, 5, 215-223.
80. Cole-Ezea, P.; Swan, D.; Shanley, D.; Hesketh, J. Glutathione peroxidase 4 has a major role in protecting mitochondria from oxidative damage and maintaining oxidative phosphorylation complexes in gut epithelial cells. Free Radic. Biol. Med. 2012, 53, 488-497.
81. Hansen, R.; Saebo, M.; Skjelbred, C. F.; Nexo, B. A.; Hagen, P. C.; Bock, G.; Bowitz Lothe, I. M.; Johnson, E.; Aase, S.; Hansteen, I. L.; et al. GPx pro198leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer. Cancer Lett. 2005, 229, 85-91.
82. Hansen, R. D.; Krath, B. N.; Frederiksen, K.; Tjonneland, A.; Overvad, K.; Roswall, N.; Loft, S.; Dragsted, L. O.; Vogel, U.; Raaschou-Nielsen, O. GPx1 Pro(198)Leu polymorphism, erythrocyte GPx activity, interaction with alcohol consumption and smoking, and risk of colorectal cancer. Mutat. Res. 2009, 664, 13-19.
83. Al-Taie, O. H.; Uceyler, N.; Eubner, U.; Jakob, F.; Mork, H.; Scheurlen, M.; Brigelius-Flohe, R.; Schottker, K.; Abel, J.; Thalheimer, A.; et al. Expression profiling and genetic alterations of the selenoproteins gi-gpx and sepp in colorectal carcinogenesis. Nutr. Cancer 2004, 48, 6-14.
84. Curran, J. E.; Jowett, J. B.; Elliott, K. S.; Gao, Y.; Gluschenko, K.; Wang, J.; Abel Azim, D. M.; Cai, G.; Mahaney, M. C.; Comuzzie, A. G.; et al. Genetic variation in selenoprotein s influences inflammatory response. Nat. Genet. 2005, 37, 1234-1241.
85. Shibata, T.; Arisawa, T.; Tahara, T.; Ohkubo, M.; Yoshioka, D.; Maruyama, N.; Fujita, H.; Kamiya, Y.; Nakamura, M.; Nagasaka, M.; et al. Selenoprotein s (SEPS1) gene À105G>A promoter polymorphism influences the susceptibility to gastric cancer in the japanese population. BMC Gastroenterol. 2009, 9, 2.
86. Al-Taie, O. H.; Seufert, J.; Mork, H.; Treis, H.; Mentrup, B.; Thalheimer, A.; Starostik, P.; Abel, J.; Scheurlen, M.; Kohrle, J.; et al. A complex DNA-repeat structure within the selenoprotein p promoter contains a functionally relevant polymorphism and is genetically unstable under conditions of mismatch repair deficiency. Eur. J. Hum. Genet. 2002, 10, 499-504.
87. Slattery, M. L.; Lundgreen, A.; Welbourn, B.; Corcoran, C.; Wolff, R. K. Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer. PLoS One 2012, 7, e37312.
88. Yang, P.; Bamlet, W. R.; Ebbert, J. O.; Taylor, W. R.; De Andrade, M. Glutathione pathway genes and lung cancer risk in young and old populations. Carcinogenesis 2004, 25, 1935-1944.
89. Ratnasinghe, D.; Tangrea, J. A.; Andersen, M. R.; Barrett, M. J.; Virtamo, J.; Taylor, P. R.; Albanes, D. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res. 2000, 60, 6381-6383.
90. Jaworska, K.; Gupta, S.; Durda, K.; Muszynska, M.; Sukiennicki, G.; Jaworowska, E.; Grodzki, T.; Sulikowski, M.; Woloszczyk, P.; Wojcik, J.; et al. A low selenium level is associated with lung and laryngeal cancers. PLoS One 2013, 8, e59051.
91. Raaschou-Nielsen, O.; Sorensen, M.; Hansen, R. D.; Frederiksen, K.; Tjonneland, A.; Overvad, K.; Vogel, U. GPx1 Pro198Leu polymorphism, interactions with smoking and alcohol consumption, and risk for lung cancer. Cancer Lett. 2007, 247, 293-300.
92. Ichimura, Y.; Habuchi, T.; Tsuchiya, N.; Wang, L.; Oyama, C.; Sato, K.; Nishiyama, H.; Ogawa, O.; Kato, T. Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J. Urol. 2004, 172, 728-732.
93. Zhao, H.; Liang, D.; Grossman, H. B.; Wu, X. Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. Urology 2005, 66, 769-774.
94. Bhatti, P.; Stewart, P. A.; Hutchinson, A.; Rothman, N.; Linet, M. S.; Inskip, P. D.; Rajaraman, P. Lead exposure, polymorphisms in genes related to oxidative stress, and risk of adult brain tumors. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 1841-1848.
95. Chen, J.; Cao, Q.; Qin, C.; Shao, P.; Wu, Y.; Wang, M.; Zhang, Z.; Yin, C. Gpx-1 polymorphism (rs1050450) contributes to tumor susceptibility: Evidence from meta-analysis. J. Cancer Res. Clin. Oncol. 2011, 137, 1553-1561.
96. Kuzuya, M.; Ando, F.; Iguchi, A.; Shimokata, H. Glutathione peroxidase 1 Pro198Leu variant contributes to the metabolic syndrome in men in a large Japanese cohort. Am. J. Clin. Nutr. 2008, 87, 1939-1944.
97. Cominetti, C.; de Bortoli, M. C.; Purgatto, E.; Ong, T. P.; Moreno, F. S.; Garrido, A. B., Jr.; Cozzolino, S. M. Associations between glutathione peroxidase-1 Pro198Leu polymorphism, selenium status, and DNA damage levels in obese women after consumption of Brazil nuts. Nutrition 2011, 27, 891-896.
98. Xiong, Y. M.; Mo, X. Y.; Zou, X. Z.; Song, R. X.; Sun, W. Y.; Lu, W.; Chen, Q.; Yu, Y. X.; Zang, W. J. Association study between polymorphisms in selenoprotein genes and susceptibility to kashin-beck disease. Osteoarthritis cartilage 2010, 18, 817-824.
99. Du, X. H.; Dai, X. X.; Xia Song, R.; Zou, X. Z.; Yan Sun, W.; Mo, X. Y.; Lu Bai, G.; Xiong, Y. M. SNP and mRNA expression for glutathione peroxidase 4 in kashin-beck disease. Br. J. Nutr. 2012, 107, 164-169.
100. Thomson, C. D.; McLachlan, S. K.; Parnell, W. R.; Wilson, N.; Wohlers, M.; Scragg, R.; Schaaf, D.; Fitzgerald, E. D. Serum selenium concentrations and dietary selenium intake of new zealand children aged 5-14 years. Br. J. Nutr. 2007, 97, 357-364.
101. Santos, L. R.; Duraes, C.; Mendes, A.; Prazeres, H.; Alvelos, M. I.; Moreira, C. S.; Canedo, P.; Esteves, C.; Neves, C.; Carvalho, D.; et al. A polymorphism in the promoter region of the selenoprotein s gene (Seps1) contributes to Hashimoto's thyroiditis susceptibility. J. Clin. Endocrinol. Metab. 2014, 99, E719-723.
102. Moses, E. K.; Johnson, M. P.; Tommerdal, L.; Forsmo, S.; Curran, J. E.; Abraham, L. J.; Charlesworth, J. C.; Brennecke, S. P.; Blangero, J.; Austgulen, R. Genetic association of preeclampsia to the inflammatory response gene seps1. Am. J. Obstet. Gynecol. 2008, 198, 336 e331-335.
103. Martinez, A.; Santiago, J. L.; Varade, J.; Marquez, A.; Lamas, J. R.; Mendoza, J. L.; de la Calle, H.; Diaz-Rubio, M.; de la Concha, E. G.; Fernandez-Gutierrez, B.; et al. Polymorphisms in the selenoprotein s gene: Lack of association with autoimmune inflammatory diseases. BMC Genomics 2008, 9, 329.
104. Cox, A. J.; Lehtinen, A. B.; Xu, J.; Langefeld, C. D.; Freedman, B. I.; Carr, J. J.; Bowden, D. W. Polymorphisms in the selenoprotein s gene and subclinical cardiovascular disease in the diabetes heart study. Acta Diabetol. 2013, 50, 391-399.
105. Marinou, I.; Walters, K.; Dickson, M. C.; Binks, M. H.; Bax, D. E.; Wilson, A. G. Evidence of epistasis between interleukin 1 and selenoprotein-S with susceptibility to rheumatoid arthritis. Ann. Rheum. Dis. 2009, 68, 1494-1497.
106. Canani, L. H.; Capp, C.; Dora, J. M.; Meyer, E. L.; Wagner, M. S.; Harney, J. W.; Larsen, P. R.; Gross, J. L.; Bianco, A. C.; Maia, A. L. The type 2 deiodinase a/g (Thr92ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2005, 90, 3472-3478.
107. Dora, J. M.; Machado, W. E.; Rheinheimer, J.; Crispim, D.; Maia, A. L. Association of the type 2 deiodinase Thr92ala polymorphism with type 2 diabetes: Case-control study and meta-analysis. Eur. J. Endocrinol. 2010, 163, 427-434.
108. Estivalet, A. A.; Leiria, L. B.; Dora, J. M.; Rheinheimer, J.; Boucas, A. P.; Maia, A. L.; Crispim, D. D2 Thr92ala and ppargamma2 Pro12ala polymorphisms interact in the modulation of insulin resistance in type 2 diabetic patients. Obesity (Silver Spring) 2011, 19, 825-832.
109. Hellwege, J. N.; Palmer, N. D.; Ziegler, J. T.; Langefeld, C. D.; Lorenzo, C.; Norris, J. M.; Takamura, T.; Bowden, D. W. Genetic variants in selenoprotein P plasma 1 gene (Sepp1) are associated with fasting insulin and first phase insulin response in hispanics. Gene 2014, 534, 33-39.
110. Misu, H.; Takamura, T.; Takayama, H.; Hayashi, H.; Matsuzawa-Nagata, N.; Kurita, S.; Ishikura, K.; Ando, H.; Takeshita, Y.; Ota, T.; et al. A liver-derived secretory protein, selenoprotein p, causes insulin resistance. Cell Metab. 2010, 12, 483-495.
111. Yang, S. J.; Hwang, S. Y.; Choi, H. Y.; Yoo, H. J.; Seo, J. A.; Kim, S. G.; Kim, N. H.; Baik, S. H.; Choi, D. S.; Choi, K. M. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: Implications for insulin resistance, inflammation, and atherosclerosis. J. Clin. Endocrinol. Metab. 2011, 96, E1325-1329.
112. Rosenberger, A.; Illig, T.; Korb, K.; Klopp, N.; Zietemann, V.; Wolke, G.; Meese, E.; Sybrecht, G.; Kronenberg, F.; Cebulla, M.; et al. Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years. BMC Cancer 2008, 8, 60.
113. Jablonska, E.; Gromadzinska, J.; Sobala, W.; Reszka, E.; Wasowicz, W. Lung cancer risk associated with selenium status is modified in smoking individuals by Sep15 polymorphism. Eur. J. Nutr. 2008, 47, 47-54.
114. Hamanishi, T.; Furuta, H.; Kato, H.; Doi, A.; Tamai, M.; Shimomura, H.; Sakagashira, S.; Nishi, M.; Sasaki, H.; Sanke, T.; et al. Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in Japanese type 2 diabetic patients. Diabetes 2004, 53, 2455-2460.
115. Huang, L.; Shi, Y.; Lu, F.; Zheng, H.; Liu, X.; Gong, B.; Yang, J.; Lin, Y.; Cheng, J.; Ma, S.; et al. Association study of polymorphisms in selenoprotein genes and kashin-beck disease and serum selenium/iodine concentration in a Tibetan population. PLoS One 2013, 8, e71411.
116. Sun, W.; Wang, X.; Zou, X.; Song, R.; Du, X.; Hu, J.; Xiong, Y. Selenoprotein P gene r25191G/A polymorphism and quantification of selenoprotein p mRNA level in patients with kashin-beck disease. Br. J. Nutr. 2010, 104, 1283-1287.